Clinical Trials Logo

Ventricular Dysfunction clinical trials

View clinical trials related to Ventricular Dysfunction.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05172115 Terminated - Pulmonary Embolism Clinical Trials

Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE

CANARY
Start date: December 22, 2018
Phase: Phase 3
Study type: Interventional

In an open-label parallel groups blinded-endpoint randomized clinical trial, the investigators aim to assess the safety and efficacy of conventional catheter-directed thrombolysis (CDT) vs anticoagulation monotherapy on outcomes of patients with acute intermediate-high risk pulmonary embolism. The investigators hypothesize that CDT will have a superior efficacy and safety compared with anticoagulation-only therapy regarding the proportion of patients with a right ventricle to left ventricle (RV/LV) ratio > 0.9 at a 3-month follow-up by an imaging core laboratory, major bleeding, severe thrombocytopenia, or vascular access complication.

NCT ID: NCT03988842 Terminated - Pulmonary Embolism Clinical Trials

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

SAFE-LYSE
Start date: July 25, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to examine the degree to which pulmonary embolism (clot) can be dissolved when treated with a very low dose of a systemic thrombolytic drug (clot buster) along with standard anticoagulant therapy as compared to the standard of care anticoagulant therapy alone.

NCT ID: NCT03089502 Terminated - Breast Cancer Clinical Trials

Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity

CORE
Start date: April 1, 2018
Phase: N/A
Study type: Interventional

Breast cancer is the leading cause of cancer among Canadian women with nearly 26,000 new cases diagnosed each year. Fortunately, advancements in diagnostic tools and curative treatments have significantly improved overall survival. However, the development of cardiac toxicity (including asymptomatic and symptomatic heart failure) associated with use of anthracycline containing chemotherapy and targeted therapies including trastuzumab limits improvements in survival for women with breast cancer. Cardiac toxicity is a life threatening complication that leads to reduced physical functioning and quality of life. The increased risk is associated with shared risk factors among cancer and heart failure and the direct influence of cancer therapy on the cardiovascular system. Cardiac rehabilitation (CR) (including exercise training and education/counselling) has been shown to improve health outcomes, reduce heart failure related hospitalizations and modestly improve mortality among individuals with non-treatment related heart failure and may benefit women with breast cancer and treatment related cardiac toxicity (BC-CT). Therefore, this single centre, randomized control trial aims to determine if participation in an exercise based CR program can improve cardiorespiratory fitness, cardiovascular function/structure and health, and quality of life among women with BC-CT.

NCT ID: NCT03032900 Terminated - Clinical trials for Right Ventricular Dysfunction

Right Ventricular Dysfunction Incidence After Major Lung Resection

RESECHO
Start date: January 1, 2017
Phase:
Study type: Observational

This study aims to describe incidence of right ventricular dysfunction after major lung resection with echocardiography criteria.

NCT ID: NCT02820441 Terminated - Clinical trials for Ventricular Dysfunction

Benefit of One Month Zopiclone Intake on Adaptative Servoventilation Compliance

ZODIAC
Start date: May 2016
Phase: Phase 4
Study type: Interventional

The study evaluate the effect of adaptative servoventilation (ASV) initiation combined with 14 days Zopiclone vs Placebo treatment in patients with central sleep apnea (CSA) syndrome.

NCT ID: NCT02757976 Terminated - Clinical trials for Heart Failure, Left Ventricular Dysfunction

Resynchronization for Ambulatory Heart Failure Trial - LV Endocardial

RAFT-LVendo
Start date: March 8, 2018
Phase: N/A
Study type: Interventional

This trial will compare two strategies for patients with Heart Failure, Left Ventricular systolic dysfunction, and intermediate QRS durations. The control group is conventional CRT. The experimental group is LVendo CRT

NCT ID: NCT02669290 Terminated - Heart Failure Clinical Trials

Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy

MUGA CRT
Start date: January 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether multiple gated acquisition (MUGA) guided lead placement improves clinical outcomes for patients needing cardiac resynchronization therapy (CRT) compared to traditional posterolateral left ventricular lead placement.

NCT ID: NCT02543632 Terminated - Heart Failure Clinical Trials

PARACHUTE V PercutAneous Ventricular RestorAtion in Chronic Heart FailUre Due to Ischemic HearT DiseasE.

P5
Start date: August 2015
Phase: N/A
Study type: Observational [Patient Registry]

Prospective, multi-center, post-market, non-randomized, nested-control, observational study of the CE marked CardioKinetix Parachute Implant System.

NCT ID: NCT01798043 Terminated - Clinical trials for Ventricular Dysfunction

Impact of Septal Vs Apical Pacing on Right and Left Ventricular Performance

Start date: January 2013
Phase: N/A
Study type: Interventional

The study aims to use cardiac MRI scans and analysis techniques to evaluate differences in cardiac function after 12 months of pacing in patients with pacing leads placed in different positions within the right ventricle (apically or septally).

NCT ID: NCT01605019 Terminated - Heart Failure Clinical Trials

The Use of CoSeal (Sealant Agent) in Patients During Left Ventricular Assist Device Surgery

Start date: June 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the use of a device called CoSeal™. CoSeal™ is an FDA approved synthetic (man-made) surgical sealant which is currently used to help stop leaks in blood vessels during surgery. This study is evaluating CoSeal™ when it is applied to various areas of the heart during the surgery to implant a Left Ventricular Assist Device (LVAD). the investigators are looking for evidence which indicates that CoSeal™ may be useful in reducing or stopping bleeding, the occurrence of micro emboli (small particles of air or blood), and the formation of cardiac adhesions (scar tissue strands that may form around the heart in the area of a previous LVAD operation) in patients who undergo LVAD implantation surgery.